Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Friedelane-Type Triterpenoids from <i>Maytenus quadrangulata</i> as Potential Anticancer Agents.

ACS omega·2026

Same author

Advancing in Acute Promyelocytic Leukemia Therapy Research: The Role of 3-Alkylpyridine Alkaloid Analogs in Overcoming Genetic and Molecular Barriers.

Anti-cancer agents in medicinal chemistry·2026

Same author

Lupane Triterpenes with Antileukemia Activity from <i>Maytenus quadrangulata</i>.

ACS omega·2026

Same author

Novel Heterocyclic Compounds Exhibit Potent Antileukemic Activity through Selective Induction of Apoptosis and HDAC8 Interaction in AML Cells.

Anti-cancer agents in medicinal chemistry·2025

Same author

Clinical Peptidomics in Acute Leukemias: Current Advances and Future Perspectives.

Journal of proteome research·2024

Same author

Retrospective Analysis of Omicron in Minas Gerais, Brazil: Emergence, Dissemination, and Diversification.

Microorganisms·2024

Search research articles

Related Experiment Video

Updated: Feb 28, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Next-Generation Biomarkers in Multiple Myeloma: Advancing Diagnosis, Risk Stratification, and Precision Therapy

Marta Marques de Carvalho Lopes¹, Laura do Amaral Xavier¹, Silvia Cristina Verde Mendes Nolasco¹

¹Postgraduate Program in Clinical and Toxicological Analysis, Department of Clinical and Toxicology Analysis, College of Pharmacy, Federal University of Minas Gerais, Prof. Moacir Gomes de Freitas Street-Pampulha, Belo Horizonte 31270-901, MG, Brazil.

Pharmaceuticals (Basel, Switzerland)

|February 27, 2026

Summary

Advanced biomarkers like ctDNA methylome and multiomics show promise for improving multiple myeloma (MM) risk stratification and treatment. These tools can overcome current diagnostic limitations for better precision strategies in plasma cell disorders.

Keywords:

biomarkers multiomics multiple myeloma precision medicine targeted therapy

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Experiment Videos

Last Updated: Feb 28, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Area of Science:

Oncohematology
Biomarker Discovery
Genomics and Omics

Background:

Multiple myeloma (MM) is a plasma cell neoplasm with complex genetics.
Non-secretory MM, lacking monoclonal protein secretion, presents diagnostic challenges.
Current diagnostic and therapeutic models have limitations in precision medicine.

Purpose of the Study:

To conduct an integrative review of genomic, epigenomic, proteomic, metabolomic, and radiomic biomarkers for MM.
To evaluate the translational potential and clinical limitations of these biomarkers.
To identify gaps in current recommendations and explore future directions.

Main Methods:

Integrative narrative review of literature from 2018-2025.
Focus on multi-omics (genomic, epigenomic, proteomic, metabolomic) and radiomic biomarkers.
Analysis of biomarker categories including ctDNA methylome, single-cell multiomics, proteomics, ex vivo assays, and PET/CT radiomics.

Main Results:

ctDNA methylome, single-cell multiomics, surface antigen proteomics, ex vivo assays, and PET/CT radiomics show significant potential.
These biomarkers can enhance risk stratification, early progression detection, and therapy selection.
Identified novel therapeutic targets and applications beyond current guideline frameworks.

Conclusions:

Advanced biomarker platforms offer enhanced precision strategies for plasma cell disorders.
Integrating these biomarkers can overcome limitations in current diagnostic and therapeutic models.
Future research should focus on the clinical implementation of these promising biomarkers.